Update on HIV Resistance and Resistance Testing

Medicinal Research Reviews

Volumn 24, Issue 1, 2004, Pages 115-125

  Sebastian, Joseph ^a   Faruki, Hawazin ^a  

^a LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Genotype phenotype; HIV resistance; Resistance mutations

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

GENOTYPE PHENOTYPE CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; VIROGENESIS; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION;

EID: 0346881255     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10057     Document Type: Review

References (64)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Ashman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Palella FJ, Chmiel JS, Moorman AC, Holmberg SD. HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002;16:1617-1626.
3. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the purified reverse transcriptase. J Virol 1995;69:5087-5094.
4. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
5. Meyer PR, Matsuura S, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999;4:35-43.
6. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001;6(Suppl 3):250-44.
7. Walter H, Schmidt B, Werwein M, Schwingel E, Korn K. Prediction of abacavir resistance from genotypic data: Impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother 2002;46:89-94.
8. Wolf K, Walter H, Schnell T, Keulen W, Beerenwinkel N, Selbig J, Vandamme A-M, Korn K, Schmidt B. The drug resistance profile of tenofovir: A story of resistance and resensitization. Antiviral Therapy 2002; 7:S16.
9. Whitcomb JM, Paxinos E, Huang M, Maranta K, Limoli C, Chappey N, Parkin NT, Hellmann NS, Petropoulos CJ. The presence of nucleoside analogue mutations (NAM's) is highly correlated with reduced susceptibility to all NRTI's. Abstract #569-T. Presented at 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Febuary, 2002.
10. Miller V, Stark T, Loeliger AE, Lang JM. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Medicine 2002;3:135-145.
11. Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, Mijch A, Petropoulos CJ, Mills J, Crowe SM. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001;15:1471-1475.
12. Demeter L, Haubrich R. Phenotypic and genotypic resistance assays: methodology, reliability and interpretations. J Acquir Immune Defic Syndr 2001;26:S3-S9.
13. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F, Girard PM. Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.
14. Craig C, Zhu C-Q, Ait-Khaled M, Tisdale M. Nucleoside reverse transcriptase inhibitor-associated resistance substitutions and susceptibility to abacavir, didanosine, and stavudine. Antiviral Ther 2002; 7(Suppl 1):S27.
15. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcom TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 2002;14:1203-1210.
16. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-F43.
17. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999;13:2349-2359.
18. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E. M98-863 Study Team. Lopinavir-Ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
19. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and anitiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
20. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001;75:7462-7469.
21. Deeks SG. Non-nucleoside reverse transcriptase inhibitor resistance. JAIDS 2001;26:S25-S33.
22. Shulman N, Zolopa AR, Passaro DJ, Mulidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. Efavirenz- and adefovir dipvoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr 2000;23:221-226.
23. Havlir DV, Eastman S, Gamst A. Richman DD. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-7899.
24. Little SJ, Daar ES, Holte S, Frost SDW, Routy JP, Markowitz M, Collier AC, Margolick J, Koup R, Conway B, Connick E, Kilby M, Wrin T, Petropoulos CJ, Hellmann NS, Richman DD. Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy. Abstract #95 presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24-28, 2002.
25. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:239-241.
26. Richman DD, Bozzette S, Morton S, Chien S, Wrin T, Dawson K, Hellmann N. The prevalence of antiretroviral drug resistance in the US. Abstract #LB-17 presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19, 2001.
27. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-durg resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
28. Hirsch M, Brun-Vezinet F, D'Aquila R, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobson DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-2426.
29. US Department of Health and Human Services and the Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.hivatis.org/trtgdlns.html. Accessed January 28, 2000.
30. Alcorn T, Faruki H. HIV resistance testing: Methods, utility, and limitations. Mol Diagn 2002;5:159-168.
31. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.
32. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001;32:774-782.
33. Haubrich R, Demeter L. Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001;26:S51-S59.
34. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type I reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
35. Schmit JC, Ruiz L, Stuyver L, Van Laethem K, Vanderlinden I, Puig T, Rossau R, Desmyter J, De Clercq E, Clotet B, Vandamme AM. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. J Virol Methods 1998;73:77-82.
36. Van Laethem K, Van Vaerenbergh K, Schmit JC, Sprecher S, Hermans P, De Vroey V, Schuurman R, Harrer T, Witvrouw M, Van Wijngaerden E, Stuyver L, Van Ranst M, Desmyter J, De Clercq E, Vandamme AM. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr 1999;22:107-118.
37. Larder B, deVroey V, Dehertogh P, Kemp S, Bloor S, Hertogs K. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Antiviral Ther 1999;4(Suppl 1):41-42.
38. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype (VirtualPhenotype). Antiviral Therapy 2000;5(Suppl 3):49
39. Verbiest W, Peeters M, Hertogs K, Schel P, Bloor S, Rinehart A, Graham N, Cohen C, Larder BA. VirtualPhenotype is concordant with actual phenotype: A retrospective analysis of data from Vira 3001. Antiviral Therapy 2000;5(Suppl 3):62.
40. Puchhammer-Stockl E, Steininger C, Geringer E, Heinz FX. Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. HIV Med 2002;3: 200-206.
41. Kellam P, Larder BA. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994;38: 23-30.
42. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
43. Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N, Heneine W. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol 2002;40:31-35.
44. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 2001;15:1671-1677.
45. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-464.
46. Piscitelli SC. The role of therapeutic drug monitoring in the management of HIV-infected patients. Curr Infect Dis Rep 2002;4:353-358.
47. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the VIRADAPT study. AIDS 2000;14:1333-1339.
48. Burger DM, Aarnoutse RE, Hugen PWH. Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis 2002;15:17-22.
49. Kempf D, Hsu A, Jiang P, Rode R, Hertogs K, Larder B, Zolopa A, Shulman N, Havlir D, Gallant J, Race E, Boller S, Swerdlow J, Jasinsky O, Renz C, Sun E. Response to Ritonavir (RTV) Intensification in indinavir recipients is highly correlated with virtual inhibitory quotient (Abstract #523). 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001.
50. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002;46:3907-3916.
51. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353:2195-2199.
52. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up. Antivir Ther 2000;5:65-70.
53. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in-patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-F93.
54. Yeni PG, Hammer SM, Carpenter CJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch. Antiretroviral Treatment for adult HIV infection in 2002. JAMA 2002;288:222-235.
55. Tural C, Ruiz L, Holtzer C, Shcapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B, Havana Study Goup. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002; 16:209-218.
56. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, DiGiambenedetto S, Cauda R, De Luca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16:369-379.
57. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM, VIRA 3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-588.
58. Lalezari J, DeJesus E, Northfelt D, Richmond G, Delhanty J, DeMasi R, Salgo M. A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating three doses of T-20 in PI-experienced, NNRTI-naïve patients infected with HIV-1. Abstract 418-W. Presented at 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
59. LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM. HIV fusion and its inhibition. Antiviral Res 2001;50:95-115.
60. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Mathews TJ. Pepetides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91:9770-9774.
61. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
62. Kemp SD, Ruiz L, Lucas AM, Bonjoch A, Martinez-Picado J, Larder BA, Clotet B. Novel mutations in a highly conserved region of HIV-1 gp41 are associated with T-20 treatment. Antiviral Therapy 2002;7:S11.
63. Greenberg ML, Davison D, Jin L, Moiser S, Melby T, Sista P, Demasi R, Miralles D, Cammack N, Mathews TJ. In vitro antiviral activity of T-1249 a second generation fusion inhibitor. Antiv Therapy 2002;7:S10 (Abstract).
64. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Enders M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM. SCH-C (SCH351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.